Wegovy maker Novo Nordisk down 4%, heads for worst day since October
Analysts pored over the details in itsĀ first-quarter results and monitored a potential rival weight loss treatment. Source link
Read MoreAnalysts pored over the details in itsĀ first-quarter results and monitored a potential rival weight loss treatment. Source link
Read MoreAmgen is among several drugmakers racing to join the red-hot weight loss drug space dominated by Novo Nordisk and Eli
Read MoreThe findings add to concerns that GLP-1s could take a bite out of the bottom lines of some of the
Read MoreNames on the move ahead of the open. Source link
Read MoreHere are the most important news items that investors need to start their trading day. Source link
Read MoreThe pharmaceutical giant plans to present the trial data at an upcoming medical conference and submit them to the U.S.
Read MoreThe review examined several drugs from Novo Nordisk, including Wegovy, Ozempic, Rybelsus, and Saxenda, but did not include Eli Lilly's
Read MoreWalgreens posted a steep net loss for the quarter as it recorded a hefty goodwill impairment charge related to its
Read MoreThe results are a sign that Altimmune can address an area of concern around weight loss drugs, which is that
Read More